Trimethoprim Injection

[Pharmacology and Toxicology] This product is an antibacterial and anti-inflammatory drug. Its mechanism is to inhibit bacterial dihydrofolate reductase and hinder bacterial folic acid metabolism. When used in combination with sulfonamides, it can double hinder bacterial metabolism, thereby enhancing the antibacterial effect. When used in combination with certain antibiotics, it also has a synergistic effect, so it is used as a synergist for sulfonamides and certain antibiotics. [Pharmacokinetics] It is absorbed within 10-30 minutes after intramuscular administration. The speed of absorption is related to the blood flow rate at the injection site. After absorption, it is widely distributed in the body. The concentration in tissues is higher than that in blood. The binding rate with plasma protein is 30%-46%. Trimethoprim is mainly excreted in urine, and 40%-50% of the dose is excreted in urine within 24 hours. A small amount is excreted through bile. The half-life (t1/2) is 8-10 hours.

Trimethoprim. Chemical name: 3,4,5-trimethoxyphenyl-2,4-pyrimidinediamine.

This product is a colorless or slightly yellow clear liquid.

It is used for the initial cases of acute simple lower urinary tract infection caused by sensitive bacteria. This product is usually used in combination with sulfonamides.

Intravenous drip: 30-100 mg at a time, 80-200 mg per day.

1. Due to the interference of this product with folic acid metabolism, adverse reactions in the blood system may occur, such as leukopenia, thrombocytopenia or methemoglobin anemia. Generally, leukopenia and thrombocytopenia are mild, and recovery is expected if the drug is discontinued in time. Folic acid preparations can also be added. 2. Allergic reactions: itching, rash, and occasionally severe exudative erythema multiforme may occur. 3. Gastrointestinal reactions such as nausea, vomiting, and diarrhea are generally mild. 4. Aseptic meningitis may occasionally occur, with symptoms such as headache, stiff neck, and nausea.

1. Contraindicated for newborns, premature infants and infants under 2 months old. 2. Contraindicated for patients with severe liver and kidney diseases. 3. Contraindicated for patients with blood diseases such as leukopenia, thrombocytopenia, purpura, etc. 4. Contraindicated for those who are allergic to this product.

Children's precautions: Not suitable for newborns, premature infants and infants under 2 months old

1. When bone marrow suppressants are used in combination with this product, the chance of leukopenia and thrombocytopenia increases. 2. When dapsone is used in combination with this product, the blood concentration of both drugs can increase. The increase in dapsone concentration can increase and aggravate adverse reactions, especially the occurrence of methemoglobinemia. 3. This product should not be used simultaneously with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor should it be used between courses of treatment with other folic acid antagonists, because it may cause bone marrow aplasia or megaloblastic anemia. 4. When used in combination with rifampicin, the clearance of this product can be significantly increased and the serum half-life can be shortened. 5. When used in combination with cyclosporine, renal toxicity can be increased. 6. This product can interfere with the hepatic metabolism of phenytoin, increase the half-life (t1/2) of phenytoin by 50%, and reduce its clearance rate by 30%. 7. When used in combination with procainamide, the renal clearance of procainamide can be reduced, resulting in an increase in the blood concentration of procainamide and its metabolite NAPA. 8. When used in combination with warfarin, it can inhibit the metabolism of the drug and enhance its anticoagulant effect.

Keep away from light and store in a sealed container.

2ml:0.1g

Yantai Luyin Pharmaceutical Co., Ltd.

• Founded in:

  1993-12-20

• Address:

  No. 102, Baishi Road, Yantai City, Shandong Province

• Tax NO.:

  91370600613415452L

• Registered Funds:

  132.074 million yuan

• Website:

  Log in to view

• Email:

  Log in to view